T. Rowe Price Investment Management, Inc. filed Amendment No. 3 to Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 18,136,166 shares of Vaxcyte Inc. common stock as of October 31, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 18,136,166 shares of Vaxcyte Inc. common stock, representing 11.6% of the class.
  • Sole voting power: The filing disclosed sole voting power over 17,359,465 shares, with shared voting power of 0.
  • Sole dispositive power: The filer reported sole dispositive power over 18,136,166 shares, with shared dispositive power of 0.
  • T. Rowe Price Capital Appreciation Fund interest: According to the filing, T. Rowe Price Capital Appreciation Fund holds 7,430,887 shares of the class, representing 5.2% of the class.
  • Event date: The date of event requiring this filing is stated as October 31, 2026.
  • Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (type IA), organized in Maryland.

T. Rowe Price Investment Management Discloses Large Vaxcyte Position in Amended 13G

T. Rowe Price Investment Management, Inc., a Maryland-incorporated investment adviser headquartered at 1307 Point Street, Baltimore, MD 21231, filed Amendment No. 3 to Schedule 13G on November 6, 2026, concerning its holdings in Vaxcyte Inc. (NASDAQ:PCVX), whose principal executive offices are located at 825 Industrial Road, Ste. 300, San Carlos, CA 94070. The triggering event date is listed as October 31, 2026.

According to the filing, T. Rowe Price Investment Management, Inc. beneficially owns 18,136,166 shares of Vaxcyte common stock (CUSIP 92243G108), equal to 11.6% of the class. The filer reported sole voting power over 17,359,465 shares and sole dispositive power over the full 18,136,166 shares, with no shared voting or dispositive authority reported.

The filing further states that T. Rowe Price Capital Appreciation Fund, for which T. Rowe Price Investment Management, Inc. serves as investment adviser, holds 7,430,887 shares within this aggregate position, representing 5.2% of the class. The filing notes that "the ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser." The certification accompanying the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by Ellen York, Vice President, on November 6, 2026.

What Was Disclosed

T. Rowe Price Investment Management, Inc. filed Amendment No. 3 to Schedule 13G reporting beneficial ownership of 18,136,166 shares, or 11.6%, of Vaxcyte Inc. common stock as of October 31, 2026, including 7,430,887 shares held through T. Rowe Price Capital Appreciation Fund.